Mesdopetam for the Treatment of Levodopa Induced Dyskinesia in Parkinson's Disease: A Randomized Phase 2b Trial
In this study mesdopetam failed to increase Good ON-time as compared to placebo. However, a statistically significant and clinically meaningful improvement in the prespecified secondary efficacy endpoint UDysRS warrants further investigation. Results from this dose finding study suggest 7.5 mg b.i.d. to be the preferred dose for further study.
Authors
- Joakim Tedroff (ORCID: https://orcid.org/0000-0003-3535-803X)
- Clas Sonesson (ORCID: https://orcid.org/0000-0003-4803-8510)
- Fabrizio Stocchi (ORCID: https://orcid.org/0000-0002-5763-0033)
- Angelo Antonini (ORCID: https://orcid.org/0000-0003-1040-2807)
- Padraig E. O’Suilleabhain (ORCID: https://orcid.org/0000-0002-2981-4791)
- Nicholas Waters (ORCID: https://orcid.org/0000-0002-8688-880X)
- Johanna Landström
Institutions
- University of Padua (IT)
- San Raffaele University of Rome (IT)
- Integrative Research Laboratories (SE)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- Movement Disorders Clinical Practice
- Published
- 2025-02-26
- DOI
- https://doi.org/10.1002/mdc3.70004
- Citations
- 6
- Primary Topic
- Neurological disorders and treatments
- Type
- article
- Field-Weighted Citation Impact
- 8.34